Summary of results from multivariate analyses, overall and stratified for diagnostic subgroups (neovascular age-related macular degeneration (nvAMD), diabetic macular oedema (DMO)) and for eyes with ≥60 Early Treatment Diabetic Retinopathy Study letters visual acuity (including patients with nvAMD and DMO) at the baseline examination
| Outcomes | OR (95% CI) | P value |
| Gaining≥5 letters at the follow-up | ||
| Overall | 1.67 (1.01 to 2.76) | 0.044 |
| nvAMD | 1.60 (0.84 to 3.07) | 0.155 |
| DMO | 2.62 (0.69 to 10.03) | 0.159 |
| ≥60 letters at baseline | 1.72 (1.04 to 2.83) | 0.035 |
| Mean difference (95% CI) | ||
| Number of injection visits per year | ||
| Overall | −0.99 (−1.59 to −0.40) | 0.001 |
| nvAMD | −0.61 (−1.39 to 0.17) | 0.124 |
| DMO | −1.14 (−2.27 to −0.01) | 0.048 |
| ≥60 letters at baseline | −0.74 (−1.34 to −0.13) | 0.018 |
| Follow-up duration (days) | ||
| Overall | 69.2 (2.4 to 136.0) | 0.042 |
| nvAMD | 33.0 (−48.6 to 114.7) | 0.426 |
| DMO | 138.2 (−32.0 to 308.3) | 0.108 |
| ≥60 letters at baseline | 67.9 (−0.8 to 136.7) | 0.053 |